Sciatica Market Scenario, Epidemiology Analysis, Key Companies Involved and Emerging Therapies

Sciatica is a pain in the lower extremity resulting from irritation of the sciatic nerve. The pain of Sciatica is typically felt from the low-back (lumbar area) to behind the thigh and can radiate down below the knee. The sciatic nerve is the largest nerve in the body and begins from nerve roots in the lumbar spinal cord in the low back and extends through the buttock area to send nerve endings down the lower limb. Radiculopathy is sometimes referred to as sciatic nerve pain.

Sciatica is an unbearable condition in which the patient experiences pain and/or paresthesia in the supply of the sciatic nerve or linked lumbosacral nerve root. Sciatica is a specific pain that is a direct result of sciatic nerve or sciatic nerve root pathology. The term sciatica is limited to the pain and irritation in nerve roots from L1 to L4 and may also involve related areas. Many times patients and clinicians use Sciatica to describe any pain arising from the lower back and radiating down to the leg.

DelveInsight's "Sciatica Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Sciatica , historical and forecasted epidemiology as well as the Sciatica market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

Download sample pages: https://www.delveinsight.com/sample-request/sciatica-market

Sciatica Disease Understanding and Treatment Algorithm

Sciatica affects mainly people of older age. The most important indications of pain arousal are radiating leg pain and related disabilities. Patients are commonly treated in primary care, but a small proportion is referred to secondary care, which may eventually end up in surgery. Synonyms for sciatica pain are lumbosacral radicular syndrome, ischias, nerve root pain, and nerve root entrapment. In maximum cases, it is caused by a herniated disc with nerve root compression, but lumbar stenosis and tumors are other possible causes. The diagnosis of Sciatica and its management is different from location to location as the surgery rates for lumbar discectomy vary widely between countries, large variation in disc surgery, even within countries can also be noticed. This may in part, be due to the scarcity of evidence on the value of diagnostic and therapeutic interventions and a lack of clear clinical guidelines reflect differences in healthcare and insurance systems.

Diagnosis 

Sciatica is mainly diagnosed by history taking and physical examination. By definition, patients mention burning pain in the leg. The patient is asked to report the distribution of the pain and whether it radiates below the knee and to draw or mark the area which may be used to evaluate the distribution. Sciatica is characterized by radiating pain that follows a dermatomal pattern. Patients may also report sensory symptoms.

Physical examination largely depends on neurological testing. The most applied investigation is the straight leg raising test or Lasègue’s sign. Patients with Sciatica may also have slight back pain, but this is usually less severe than the leg pain. The diagnostic value of patient history and physical examination has not been well studied. No history examination or physical tests have both high sensitivity and high specificity. The sensitivity of the straight leg raising test is estimated to be very high with a corresponding specificity of being low. A thorough differential list is important in considering a diagnosis of Sciatica and should include- Herniated lumbosacral disc, muscle spasm, nerve root impingement, piriformis syndrome and others.

Treatment 

Currently, the market of Sciatica holds treatment options that are supportive in nature, such as conservative (nonsurgical) and surgical methods. Conservative treatment of Sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies.   

Patients are mostly benefited by physical therapy, which includes multiple options to get relief from the unbearable pain. Several types of deep massages, hot and cold therapies to release muscle tension and pressure thereby enabling the blood flow are preferred.

Download full report: https://www.delveinsight.com/report-store/sciatica-market

Sciatica Epidemiology  

Key Findings

This section provides glimpses of the Sciatica epidemiology in the 7MM.

·         The total prevalent population of Sciatica in the seven major markets ranges was 27,022,660 in 2017

·         Delveinsight has also analyzed the diagnosed prevalent population of lumbar disc herniation. In 2017, the number of diagnosed prevalent cases of lumbar disc herniation was 7,358,250, which will increase in the forecast period.

·         In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States.

·         In 2017, the surgery eligible patient pool in the US was 1,082,736, which is anticipated to increase in the forecast period.

·         The age-specific prevalence of Sciatica was maximum in the age group 45–54 with 2,043,958 cases in 2017 in the US while the lowest number of cases were found in 18–34 age group with 1,218,199 cases in 2017.

·         In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States. On the other hand, a similar trend was not observed in EU5, and Japan wherein females are more predominant than males.

Sciatica Drug Chapters

Marketed Drugs 

The report provides the details of the marketed product available for Sciatica treatment. 

Sciatica Emerging Drugs 

SP-102 (Semdexa): Semnur Pharmaceuticals/Scilex Holding Company

SP-102 is the first nonopioid corticosteroid formulated as a viscous gel injection, which is under development for the treatment of lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents or particulates. The US Food and Drug Administration (FDA) has granted SP-102 Fast Track Designation for the treatment of lumbar radicular pain/sciatica. SP-102 is currently undergoing crucial Phase III trials with data readout expected in the first half of 2020

Condoliase (Hernicore): Seikagaku Corporation

Hernicore (Condoliase/SI-6603) is developed by Seikagaku Corporation and marketed in Japan which is used as a chemonucleolysis treatment to break down selected components of the IVD, primarily within the nucleus pulposus. This reduces its water content and volume, thereby relieving disc pressure and compression on the spinal nerve root. The treatment for lumbar disc herniation SI-6603, an injectable drug containing condoliase, an enzyme that selectively degrades glycosaminoglycan (GAG) in the herniated nucleus pulposus, and thus when injected directly into the intervertebral disc can reduce pressure on nerves (the source of pain) caused by the herniation, thereby providing relief from the pain. Glycosaminoglycans (GAG) are acidic mucopolysaccharides consisting of a repetitive disaccharide structure of amino sugar and uronic acid or galactose. SI-6603 does not break down proteins, so it does not affect surrounding tissue, such as blood vessels and nerves.

SX600: SpineThera

SX600, a nonopioid epidural steroid injection, a sustained-release, micro-suspension corticosteroid to address the unique requirements to treat back pain. The active ingredient in SX600 is dexamethasone acetate, which has been reformulated into an injectable micro-suspension containing microparticles that are smaller than the particles in a standard corticosteroid suspension and smaller than a red blood cell. The active drug is encapsulated within these tiny, biodegradable microparticles, which provide sustained release delivery of dexamethasone. 

Clonidine Micropellets: Sollis Therapeutics

Clonidine is an alpha-2 agonist, an investigational extended-release form of a well-known analgesic and anti-inflammatory medication. The extended-release form is referred to as a “clonidine micropellet” and allows for localized delivery of clonidine to the affected nerves to reduce pain and inflammation via simple, one-time, epidural injection. Moreover, clonidine has been approved for systemic administration by the FDA for several uses because of its potent activity. The first product approved was introduced in 1974 as an orally administered pill for the treatment of hypertension. In 2010, clonidine was also approved for the treatment of attention deficit hyperactivity disorder and was usually administered with a patch.

Products detail in the report…

Sciatica Market Outlook

Patients who have Sciatica are best aided by a treatment plan that is individualized based on the patient’s symptoms, diagnosis, and response to various treatments. Many cases of Sciatica go away within a few weeks using conservative treatment methods. However, this is not the case for all patients. For some, Sciatica can last much longer, even for several months.

Currently, the market of Sciatica holds treatment options that are supportive in nature, such as conservative (nonsurgical) and surgical methods. Conservative treatment of Sciatica further includes physical therapy, behavioral therapies, or pharmacological therapies.  

According to DelveInsight, Sciatica market in 7MM is expected to change in the study period 2017–2030.

Key Findings

This section includes a glimpse of the Sciatica market in 7MM.

·         According to Delveinsight estimates, the United States accounts for the largest market size of Sciatica, in comparison to Japan and EU5 (the United Kingdom, Germany, Italy, France, and Spain).

·         The market size of Sciatica in the seven major markets is USD 2,047.28 Million in 2017.

·         Japan accounts for the least market size in 7MM during the forecast period 2017–2030, at a CAGR of 4.24% for the study period (2017–2030)

·         Among the EU5 countries, Germany had the highest market size, with USD 158.45 Million in 2017, while Spain had the smallest market size of Sciatica with USD 91.82 Million.

·         Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Sciatica. Owing to the positive outcomes of the upcoming products during the developmental stage by key players such as Scilex Holdings, Seikagaku Corporation have the potential to create a significant positive shift in the Sciatica Market Size 

Request for sample pages: https://www.delveinsight.com/sample-request/sciatica-market

Download full report: https://www.delveinsight.com/report-store/sciatica-market